Home
Search

News

Get the latest on BIO's announcements, positions and views on everything from healthcare to biofuels. 

Press Releases
Browse All
BIO Applauds FTC Settlement Decision
Yesterday the Federal Trade Commission (FTC) announced the decision to settle its Amgen-Horizon merger challenge. The settlement will give the Commission the relief it needs to protect competition, while allowing rare disease patients to enjoy the…
Learn more
BIO Podcast 2023 Fall Season Launch
New Season of I am BIO Podcast Covers Birds, Bees, and Bugs Fall 2023 season explores biotech solutions for wildlife conservation, bee health, drug-resistant bugs, and more Washington – (Aug. 30, 2023) – Save the date―the Biotechnology Innovation…
Learn more
BIO Statement on CMS Announcement of First 10…
The Biden Administration today unveiled the first 10 prescription drugs that will be subject to price controls under the Inflation Reduction Act (IRA). Rachel King, BIO interim President and CEO, made the following statement: The Medicare price…
Learn more
Letters, Testimony, & Comments
Browse All
BIO Comments to FDA on Using Artificial…
In response to the agency's request for information (Docket No. FDA-2023-N-0743-0002), BIO provides detailed comments.
Learn more
BIO Comments on the NIH Technology Transfer…
BIO provides detailed comments in advance of the July 31, 2023 NIH Workshop, “Transforming Discoveries into Products: Maximizing NIH’s Levers to Catalyze Technology Transfer.
Learn more
BIO Comment on EU Compulsory Licensing Legislation
Learn more
Amicus Briefs
Browse All
BIO FILES AMICUS BRIEF CHALLENGING FTC’S…
The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge the Federal Trade Commission (FTC) lawsuit to block the acquisition of Horizon by Amgen. The amicus brief was filed in the U.S. District Court, Northern…
Learn more
BIO Files Amicus Brief in U.S. ex rel. Scutte v…
BIO has filed an amicus brief in U.S. ex rel. Scutte v. SuperValu Inc., which addresses the issue of the intent requirement under the False Claims Act (FCA). Specifically, BIO urges the Court to uphold the view that a firm does not…
Learn more
BIO JOINS AMICUS BRIEF CHALLENGING COURT’S…
The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge a District Court’s unprecedented ruling (related to a single drug known as mifepristone) that would create regulatory barriers and potentially upend FDA’s…
Learn more
Blog Posts
Browse all Blogs
Placeholder Image
Creating Higher Educational Pipelines in Biotechnology that addresses Diversity, Equity, and Inclusion
March 19, 2023
Biotech is a cornerstone to serving the world’s health-related needs for all demographics; but in the United States, the industry’s workforce does not reflect the demographics it serves, to the detriment of both the…
Placeholder Image
2022 BIO International Convention Innovation Zone Company Snapshot: Applikate
June 7, 2022
Thousands of global biotechnology and biopharmaceutical leaders will gather at the 2022 BIO International Convention in San Diego June 13-16 for four exciting days of networking, programming, and partnering…
primetime life sciences
2022 BIO International Convention Innovation Zone Company Snapshot: Primetime Life Sciences
June 6, 2022
The 2022 BIO International Convention is back and in person this year. Thousands of global biotechnology and biopharmaceutical leaders will gather in San Diego as we celebrate how scientific discoveries and innovations…